Inhibitory effect of leflunomide on hepatic fibrosis induced by CCl 4 in rats

Acta Pharmacologica Sinica

Volumn 25, Issue 7, 2004, Pages 915-920

  Yao, Hong Wei ^a,b   Li, Jun ^b   Chen, Ji Qiang ^a   Xu, Shu Yun ^b  

^a ZHEJIANG UNIVERSITY   (China)

^b ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

Hepatic fibrosis; Leflunomide; Nitric oxide; Nuclear factor kappa B; Transforming growth factor beta

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CARBON TETRACHLORIDE; HYALURONIC ACID; HYDROXYPROLINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LEFLUNOMIDE; NITRIC OXIDE; PROCOLLAGEN; PROCOLLAGEN 3; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; DRUG SCREENING; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBRIN FORMATION; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; INJECTION; LIVER FIBROSIS; MALE; NONHUMAN; PROTEIN EXPRESSION; RADIOIMMUNOASSAY; RAT; RAT STRAIN; SPECTROPHOTOMETRY; SPLEEN;

ADJUVANTS, IMMUNOLOGIC; ALANINE TRANSAMINASE; ANIMALS; ASPARTATE AMINOTRANSFERASES; CARBON TETRACHLORIDE POISONING; COLLAGEN TYPE III; HYDROXYPROLINE; ISOXAZOLES; LIVER; LIVER CIRRHOSIS, EXPERIMENTAL; MALE; NF-KAPPA B; NITRIC OXIDE; RATS; RATS, SPRAGUE-DAWLEY; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1;

EID: 3142780623     PISSN: 16714083     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Sanders S, Harisdangkul V. Leflunomide for the treatment of rheumatoid arthritis and autoimmunity. Am J Med Sci 2002; 323: 190-3.
2. Williams JW, Mital D, Chong A, Kottayil A, Millis M, Longstreth J, et al. Experience with leflunomide in solid organ transplantation. Transplantation 2002; 73: 358-66.
3. Kessel A, Toubi E. Leflunomide in systemic lupus erythematosus. Harefuah 2002; 141: 355-7, 409.
4. Mall JW, Myers JA, Xu X, Saclarides TJ, Philipp AW, Pollmann C. Leflunomide reduces the angiogenesis score and tumor growth of subcutaneously implanted colon carcinoma cells in the mouse model. Chirurg 2002; 73: 716-20.
5. Lucient J, Dias VC, LeGatt DF, Yatscoff RW. Blood distribution and single-dose pharmacokinetics of leflunomide. Ther Drug Monit 1995; 17: 454-9.
6. Li J, Yao HW, Jin Y, Zhang YF, Li CY, Xu SY. Pharmacokinetics of leflunomide in Chinese healthy volunteers. Acta Pharmacol Sin 2002; 23: 551-5.
7. 771726) blocks TNF-dependent nuclear factor-κB activation and gene expression. J Immunol 1999; 162: 2095-102.
8. Manna SK, Mukhopadhyay A, Aggarwal BB. Leflunomide suppresses TNF-induced cellular responses: effects on NF-kappa B, activator protein-1, c-Jun N-terminal protein kinase, and apoptosis. J Immunol 2000; 165: 5962-9.
9. Jankovic V, Samardzic T, Stosic-Grujicic S, Popadic D, Trajkovic V. Cell-specific inhibition of inducible nitric oxide synthase activation by leflunomide. Cell Immunol 2000; 199: 73-80.
10. Beljaars L, Meijer DK, Poelstra K. Targeting hepatic stellate cells for cell-specific treatment of liver fibrosis. Front Biosci 2002; 7: e214-22.
11. 4- plus ethanol-induced liver cirrhosis in rats. Liver 1998; 18: 180-5.
12. Hellerbrand C, Jobin C, Iimuro Y, Licato L, Sartor RB, Brenner DA. Inhibition of NFkappaB in activated rat hepatic stellate cells by proteasome inhibitors and an IkappaB superrepressor. Hepatology 1998; 27: 1285-95.
13. Lang A, Schoonhoven R, Tuvia S, Brenner DA, Rippe RA. Nuclear factor kappaB in proliferation, activation, and apoptosis in rat hepatic stellate cells. J Hepatol 2000; 33: 49-58.
14. Wright MC, Issa R, Smart DE, Trim N, Murray GI, Primrose JN, et al. Gliotoxin stimulates the apoptosis of human and rat hepatic stellate cells and enhances the resolution of liver fibrosis in rats. Gastroenterology 2001; 121: 685-98.
15. Yao HW, Li J, Jin Y, Zhang YF, Li CY, Xu SY. Effect of leflunomide on immunological injury in mice. World J Gastroenterol 2003; 9: 320-3.
16. Yao HW, Jin Y, Li J, Zhang YF, Li CY, Xu SY. Effect of leflunomide on immunological injury. Acta Pharm Sin 2002; 36: 727-30.
17. Yao HW, Jin Y, Li J, Zhang YF, Li CY, Xu SY. Effect of leflunomide on the acute chemical injury. Anhui Yiyao 2002; 5: 7-9.
18. Zhang JP, Zhang M, Zhou JP, Liu FT, Zhou B, Xie WF, et al. Antifibrotic effects of matrine on in vitro and in vivo models of liver fibrosis in rats. Acta Pharmacol Sin 2001; 22: 183-6.
19. Bergman T, Loxley R. Two improved and simplified methods for the spectrophotometric determination of hydroxyproline. Anal Chem 1963; 35: 1961-5.
20. WU J, Norton PA. Animal models of liver fibrosis. Scand J Gastroenterol 1996; 31: 1137-43.
21. Ghost S, May MJ, Kopp EB. NF-κB and Rel proteins: evolutionary conserved mediators of immune responses. Annu Rev Immunol 1998; 16: 225-60.
22. Wu J, Zem MA. Hepatic stellate cells: a target for the treatment of liver fibrosis. J Gastroenterol 2000; 35: 665-72.
23. Nadler EP, Dickinson EC, Beerstolz D, Alber SM, Watkins SC, Pratt DW, et al. Scavenging nitric oxide reduces hepatocellular injury after endotoxin challenge. Am J Physiol Gastrointest Liver Physiol 2001; 281: G173-G181.
24. Rockey DC, Chung JJ. Inducible nitric oxide synthase in rat hepatic lipocytes and the effect of nitric oxide on lipocyte contractility. J Clin Invest 1995; 95: 1199-206.
25. Fang JZ, Gao JS, Wu H. Implication of dynamic changes of nitric oxide in rats of experimental liver fibrosis. Immunol J 1997; 13: 26-8